

Docking Study of Modified Acetohexamide and Modified Metformin with IRAK Protein

Tahir Naqqash, Nadir Bilal, Syed Bilal Hussain, Syed Aun Muhammad and Muhammad Imran Qadir*

Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Multan, Pakistan

***Corresponding author:** Muhammad Imran Qadir, Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Multan, Pakistan



ARTICLE INFO

Received: 📅 December 02, 2021

Published: 📅 December 10, 2021

Citation: Tahir Naqqash, Nadir Bilal, Syed Bilal Hussain, Syed Aun Muhammad, Muhammad Imran Qadir. Docking Study of Modified Acetohexamide and Modified Metformin with IRAK Protein. Biomed J Sci & Tech Res 40(3)-2021. BJSTR. MS.ID.006456.

ABSTRACT

In the recent years much of the scientific efforts have been shifted towards computer and its applications to assist explorations in the area of biology sciences and developed a new discipline as bioinformatics. One of the important aspect of this area of research the designing of drugs based on the in-silico methods, which ultimately are validated through wet laboratory techniques. The present efforts have been prepared to dock modified specific ligand for diabetes mellitus treatment. We have an IRAK protein which is responsible of diabetes mellitus. We have concluded from the present study that the modified acetohexamide ligand has great results from the molecular docking.

Keywords: Acetohexamide Modified Ligand; Diabetes; IRAK Protein

Introduction

In the recent years much of the scientific efforts have been shifted towards computer and its applications to assist explorations in the area of biology sciences and developed a new discipline as bioinformatics [1-3]. One of the important aspect of this area of research the designing of drugs based on the in-silico methods, which ultimately are validated through wet laboratory techniques [4]. Objective of the present study was to evaluate the docking study of modified acetohexamide and modified metformin with IRAK protein, which is involved in diabetes mellitus.

Materials and Methods

The Protein sequence which is responsible for diabetes mellitus retrieved from NCBI. This IRAK protein has been used in the sequence. Briefly, acetohexamide and its modified structure; moreover metformin and its modified structure were docked with IRAK protein. The protein data bank was used to retrieve the

structure of the protein. Both the protein and ligands were present in sdf files and were converted into pdb in the discovery studio, then these files were convert into pdbqt files in the auto dock software. And finally all the structures were docked with IRAK protein by using vina tool. Detailed modifications of the parent compounds/ drugs are given here.

Modified Acetohexamide

Acetohexamide was modified as:

- We change H45 to S45
- Then attached O34 to N1

Modified Metformin

Metformin was modified as:

- Changed H9 into N9.

b) Then H8 was changed into Cl8.

Structure of modified acetohexamide and modified metformin are given in Figures 1 & 2.




Figure 1: Modified acetohexamide.




Figure 2: Modified metformin.

Results and Discussion

Docking results of our study are given in Table 1. There were 9 pockets in total. Modified acetohexamide in pocket 5 gave lower bonding energy while modified metformin gave lower bonding energy in many pockets.

Table 1: Docking results of our study.

Mode	1	2	3	4	5	6	7	8	9
Acetohexamide	-8.2	-8.0	-8.0	-7.9	-7.7	-7.7	-7.7	-7.6	-7.5
Acetohexamide modified	-8.1	-8.0	-7.9	-7.9	-7.8	-7.4	-7.4	-7.4	-7.3
Metformin original	-4.8	-4.6	-4.5	-4.4	-4.4	-4.3	-4.2	-4.2	-4.1
Metformin modified	-4.9	-4.7	-4.5	-4.4	-4.3	-4.3	-4.3	-4.3	-4.1

ADMIT Properties

ADMIT Properties of the candidates are given in Table 2.

Table 2: ADMIT Properties of the candidates.

STRUCTURE	MlogP	S+logP	S+logD	RuleOf5	RuleOf5_code	MWt	M_NO	T_PSA	HBDH
Acetohexamide	1.661	2.247	1.654	0.000		324.401	6.000	92.340	2.000
Acetohexamide modified	2.684	2.682	2.682	0.000		330.328	3.000	54.370	1.000
Metformin	-0.329	-0.819	-2.272	0.000		129.166	5.000	88.990	5.000
Metformin modified	-0.742	-1.285	-1.904	1.000	Hb	150.571	6.000	115.010	7.000

Drug Scoring by DSX-Online

Drug scoring of the modified drugs are given in Table 3 which were obtained by DSX-online. When we discuss the results of our study, we have come to know that modified metformin was a very good option to develop in real structure and go through wet laboratory validation. It showed very worthy outcome as it showed lower (-4.9) bonding energy as compared to the original compound.

Table 3: Drug scoring of the modified drugs.

Ligand	RMSD	Rank score	Score
Acetihexamide modified	none	1	-46
Metformin modified	none	1	-40

Conclusion

Molecular docking study provides an opportunity to identify good drugs that may further be used for validation in actual.

References

1. Ahmad FK, He Z, King GL (2005) Molecular targets of diabetic cardiovascular complications. *Curr Drug Targets* 6(4): 487-494.
2. Bharatam PV, Patel DS, Adane L, Mittal A, Sundriyal S (2007) Modeling and informatics in designing anti-diabetic agents. *Curr Pharm Des* 13(34): 3518-3530.
3. Bagust A, Beale S (2005) Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. *Health Econ* 14(3): 217-30.
4. Coyle D, Lee KM, O'Brien BJ (2002) The role of models within economic analysis: focus on type 2 diabetes mellitus. *Pharmacoeconomics* 20(Suppl 1): 11-9.

ISSN: 2574-1241

DOI: 10.26717/BJSTR.2021.40.006457

Muhammad Imran Qadir. Biomed J Sci & Tech Res



This work is licensed under Creative Commons Attribution 4.0 License

Submission Link: <https://biomedres.us/submit-manuscript.php>



Assets of Publishing with us

- Global archiving of articles
- Immediate, unrestricted online access
- Rigorous Peer Review Process
- Authors Retain Copyrights
- Unique DOI for all articles

<https://biomedres.us/>